Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Quaker Houghton Q4 2025 Earnings Call - Asia Pacific Momentum and Share Gains Drive EBITDA Recovery Despite North America Operational Hits
Quaker Houghton closed 2025 with a mixed but constructive quarter. Adjusted EBITDA rose 11% in Q4 and adjusted EPS climbed 24%, driven by sustained share gains and a strong Asia Pacific performance th...
- Q4 net sales $468 million, up 6% year-over-year; adjusted EBITDA $72 million, up 11% versus prior year.
- Q4 non-GAAP diluted EPS $1.65, a 24% increase year-over-year; full-year non-GAAP EPS $7.02.
- Organic volumes declined less than 1% in Q4, but management says volumes would have been flat without December operational issues in U.S. plants and a customer outage.
- +13 more takeaways
Galapagos Q4 2025 / FY 2025 Earnings Call - EUR3bn Cash Pile Fuels Pivot to Late-Stage Dealmaking with Gilead Support
Galapagos closed 2025 with roughly EUR 3 billion in cash and a management reset focused on buying or partnering into clinically de-risked, late-stage immunology and oncology assets. The reported opera...
- Year-end cash and investments about EUR 2,998 million, giving Galapagos roughly EUR 3.0 billion of deployable capital at Dec 31, 2025.
- Operating profit of EUR 295.1 million in 2025 versus an operating loss of EUR 188.3 million in 2024, driven primarily by a EUR 1,069 million release of deferred revenue related to the 2019 OLCA.
- The OLCA-related contract liability, originally approximately EUR 2.3 billion, was derecognized after 2025 amendments and an assessment that no remaining obligations justified carrying it, and no cash tax impact is expected for 2025.
- +12 more takeaways
Woodside Petroleum FY2025 Earnings Call - Record production cushions softer prices as Scarborough nears startup
Woodside posted an operational year to brag about: record annual production of 198.8 million boe and strong project delivery offsetting lower realized prices. Underlying NPAT was $2.6 billion, free ca...
- Woodside delivered record FY2025 production of 198.8 million barrels of oil equivalent, above guidance, driven by Sangomar and high reliability across the portfolio.
- Underlying net profit after tax was $2.6 billion for 2025, down versus 2024 on lower realized prices but supported by higher volumes.
- Free cash flow totaled $1.9 billion despite elevated capex, enabling a final dividend of $0.59 per share and a full-year fully franked dividend of $1.12 per share (80% payout of underlying NPAT).
- +15 more takeaways
Kratos Defense & Security Solutions Q4 2025 Earnings Call - Hypersonics, engines and space poised to lift revenue as backlog and pipeline hit records
Kratos closed FY2025 with momentum, reporting a stronger-than-expected Q4 with 20% organic revenue growth, $345.1 million in revenue, adjusted EBITDA of $34.1 million, a record backlog of $1.573 billi...
- Q4 2025 results beat expectations, with revenue of $345.1 million, 20% organic Q4 YoY growth, and adjusted EBITDA of $34.1 million, slightly above guidance.
- Company ended the quarter with a record backlog of $1.573 billion and a record opportunity pipeline of $13.7 billion, signaling broad demand across product lines.
- Management expects hypersonics to double from 2025 to ~ $400 million in 2026, then grow roughly 75% to ~ $700 million in 2027, driven by 120 Zeus and Oriole SRMs on order and new hypersonic facilities.
- +12 more takeaways
Vir Biotechnology Q4 2025 Earnings Call - Astellas Deal and Phase I VIR-5500 Data De-risk and Accelerate Prostate Cancer Push
Vir Biotechnology used its Q4 2025 update to do two things at once, and do them loudly. The company struck a landmark collaboration with Astellas that injects upfront capital, shares development costs...
- Vir announced a strategic collaboration with Astellas for VIR-5500, a dual-masked PRO-XTEN PSMA-targeting T-cell engager, to co-develop and co-commercialize globally.
- Financial terms: $315 million upfront consideration split as $240 million cash and $75 million equity at $10.36 per share, plus a $20 million manufacturing tech-transfer milestone and up to $1.37 billion in additional development, regulatory, and ex-US commercial milestones, for total potential consideration of $1.7 billion.
- Commercial split: U.S. profits shared 50/50, Vir holds an option to co-promote in the U.S., Astellas receives exclusive ex-U.S. rights, Vir gets tiered double-digit royalties and ex-US milestones.
- +11 more takeaways
U.S. Global Investors Q2 2026 Earnings Call - Gold momentum, ETF inflows and buybacks offset a one-time tax hit
Management pitched a clear narrative: gold and thematic ETFs are driving asset and revenue momentum, the balance sheet is healthy, and the company is using opportunistic share buybacks plus a high sha...
- Assets under management rose to approximately $1.7 billion, with average AUM for the period $1.48 billion.
- Operating revenues for the quarter were $2.5 million, up 13% year over year driven by AUM gains, especially in equity mutual funds.
- Pre-tax income reported was $535,000, and quarterly EBITDA per share improved to $0.04 in December.
- +13 more takeaways
Backblaze Q4 2025 Earnings Call - Adjusted Free Cash Flow Positive as Company Bets on NeoClouds with a $15M+ TCV Win
Backblaze closed 2025 with a milestone quarter, reporting Q4 revenue of $37.8 million, adjusted EBITDA margin of 28%, and the company’s first Adjusted Free Cash Flow positive quarter as a public compa...
- Q4 revenue was $37.8 million, in line with guidance; full-year total company revenue grew 14% year-over-year.
- Backblaze reported its first Adjusted Free Cash Flow positive quarter as a public company, $4 million in Q4 representing an 11% margin.
- Q4 adjusted EBITDA margin reached 28%, roughly double the prior year, with some outperformance driven by non-recurring items such as variable compensation alignment and office restructuring savings.
- +16 more takeaways
Allison Transmission Q4 2025 Earnings Call - Dana Off-Highway Deal Closed, $120M Synergies Promised, 2026 Guide Built Conservatively
Allison closed the acquisition of Dana’s Off-Highway Drive & Motion Systems on January 1, creating a two‑segment company and a significantly expanded global footprint. Management is bullish on long‑te...
- Allison completed the acquisition of Dana Incorporated’s Off‑Highway Drive & Motion Systems business effective January 1, creating a combined company with roughly 14,000 employees across 25 countries.
- The combined company will operate as two business units: Allison Transmission led by Fred Bohley, and Allison Off‑Highway Drive & Motion Systems led by Craig Price, both reporting to CEO David Graziosi.
- Full‑year 2025 revenue for the legacy Allison Transmission business declined 7% year‑over‑year, while adjusted EBITDA margin expanded 140 basis points to 37.5%.
- +16 more takeaways
DMC Global Fourth Quarter 2025 Earnings Call - Tariffs and High Rates Crush Margins Despite Big Debt Paydown
DMC reported a quarter of shrinking top line and squeezed margins, even as management delivered a striking cleanup of the balance sheet. Consolidated sales fell 6% year over year to $143.5 million, ad...
- Net debt fell to $18.7 million at year end, a 67% reduction from end of 2024, driven by strong cash flow and debt paydown; cash on hand roughly $32 million.
- Consolidated Q4 sales declined 6% year over year to $143.5 million, reflecting weakness across the energy and construction end markets.
- Adjusted EBITDA attributable to DMC was negative $1.6 million in Q4, which included about $7 million of discrete accounts receivable and inventory write-offs at DynaEnergetics.
- +12 more takeaways
Summit Therapeutics Q4 2025 Earnings Call - Squamous cohort enrollment complete, interim PFS readout set for Q2 2026
Summit used this quarter to push timelines and broaden the ivonesimab story. The company completed screening for the squamous cohort of the pivotal HARMONi-3 study and has added an interim PFS analysi...
- HARMONi-3 squamous cohort: screening completed, last patient to be randomized within weeks, and an interim PFS analysis is planned for Q2 2026; overall survival will be immature at that interim look.
- HARMONi-3 non-squamous cohort: enrollment expected to complete in H2 2026; final PFS events anticipated by H1 2027.
- Regulatory and BLA status: FDA accepted Summit’s BLA for the HARMONi (EGFR-mutant post-TKI) indication; PDUFA target date is November 14, 2026. FDA has indicated a statistically significant OS benefit is necessary in that setting.
- +11 more takeaways